Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
Conditions
Breast
Volunteers
Health Professionals
What is the purpose of this trial?
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
- Trial withSouthwest Oncology Group (SWOG)
- Start Date06/10/2020
- End Date07/15/2027
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alessia Donadio, MD
- Anamika Katoch, MD
- Andrea Martelli
- Andrea Silber, MD
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS
- Benjamin Newton, MD
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Javin Brita
- Jaykumar Thumar, MBBS, MD
- Jeremy Kortmansky, MD
- Johanna LaSala, MD
- Justin Persico, MD
- Karishma Mehra, MBBS
- Katherine Harvey, MD, MPH
- Kathryn Daniels
- Kelsey Martin, MD
- Kerin Adelson, MD
- Kert Sabbath, MD, FACP
- Khanh Nguyen, MD
- Kristen Hoxie
- Lajos Pusztai, MD, DPhil
- Madeline Santiago
- Michael Cohenuram, MD
- Michael DiGiovanna, MD, PhD
- Michelle Corso
- Neal Fischbach, MD
- Pawan Karanam, MD
- Sarah Carlson
- Stephen Lattanzi, MD
- Su Hsien Lim, MD
- Susan Rabinowe, MD
- Tara Sanft, MD
- Victor Chang, MD
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Zia Rahman, MD
- Last Updated07/15/2021
- Study HIC#2000024170